Selective bladder-preserving therapy for muscle-invasive cancer

被引：0
作者：
Niall M. Heney
Donald S. Kaufman
William U. Shipley
机构：
[1] Massachusetts General Hospital,Department of Radiation Oncology
[2] Harvard Medical School,undefined
来源：
Nature Reviews Clinical Oncology | 2009年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Transurethral resection of the bladder and adjuvant chemoradiation can permit eradication of the tumor and micrometastases. Close monitoring by sequential cystoscopy and biopsy can achieve similar survival outcomes to radical cystectomy, and could avoid invasive treatment.
引用
收藏
页码：193 / 194
页数：1
相关论文
共 50 条
[31]   Comparison of Outcomes in Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Chemoradiation [J].
Zhong, J. ;
Switchenko, J. ;
Jegadeesh, N. ;
Gillespie, T. W. ;
Master, V. A. ;
Nieh, P. ;
Alemozaffar, M. ;
Kucuk, O. ;
Carthon, B. ;
Filson, C. P. ;
Jani, A. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02) :S93-S94
[32]   Preserving continence in muscle-invasive bladder cancer [J].
Anthony Costello ;
Rajiv Goel .
Nature Reviews Clinical Oncology, 2009, 6 :194-196
[33]   Preserving continence in muscle-invasive bladder cancer [J].
Costello, Anthony ;
Goel, Rajiv .
NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (04) :194-196
[34]   Editorial Comment from Dr Kobayashi to Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and partial cystectomy [J].
Kobayashi, Takashi .
INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 (10) :1013-1013
[35]   Bladder-preserving therapy using a real-time tumor-tracking radiotherapy system for muscle-invasive bladder cancer. [J].
Miyata, Haruka ;
Osawa, Takahiro ;
Frumido, Jun ;
Kikuchi, Hiroshi ;
Matsumoto, Ryuji ;
Abe, Takashige ;
Maruyama, Satoru ;
Nishioka, Kentaro ;
Shimizu, Shinichi ;
Hashimoto, Takayuki ;
Shirato, Hiroki ;
Shinohara, Nobuo .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[36]   Editorial Comment from Dr Kojima to Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and partial cystectomy [J].
Kojima, Takahiro .
INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 (10) :1012-1012
[37]   Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes [J].
Shahbaz, Muhammad ;
Ammar, Asif ;
Wang, Yuliang ;
Farhaj, Zeeshan ;
Qiao, Liang ;
Niu, Jun .
INTERNATIONAL BRAZ J UROL, 2021, 47 (01) :93-99
[38]   Nuclear Factor-κB Overexpression is Correlated with Poor Outcomes after Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer [J].
Chiang, Yun ;
Wang, Chung-Chieh ;
Tsai, Yu-Chieh ;
Huang, Chao-Yuan ;
Pu, Yeong-Shiau ;
Lin, Chia-Chi ;
Cheng, Jason Chia-Hsien .
JOURNAL OF CLINICAL MEDICINE, 2019, 8 (11)
[39]   Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer—a valid option for cisplatin-unfit patients? [J].
C. R. Arnold ;
A. K. Lindner ;
G. Schachtner ;
G. Tulchiner ;
N. Tulchiner ;
J. Mangesius ;
M. Maffei ;
W. Horninger ;
O. Kouvaiou ;
P. Lukas ;
U. Ganswindt ;
R. Pichler ;
S. Skvortsov .
Strahlentherapie und Onkologie, 2022, 198 :25-32
[40]   Vinorelbine in Bladder-Preserving Multimodality Treatment for Muscle-Invasive Bladder Cancer - a Valid Option for Cisplatin-Unfit Patients? [J].
Arnold, C. ;
Lindner, A. ;
Schachtner, G. ;
Tulchiner, G. ;
Tulchiner, N. ;
Mangesius, J. ;
Maffei, M. ;
Horninger, W. ;
Kovaiou, O. ;
Lukas, P. ;
Ganswindt, U. ;
Pichler, R. ;
Skvortsov, S. .
STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) :S27-S28
12345